Mueller Ivo, Genton Blaise, Betuela Inoni, Alpers Michael P
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Hum Vaccin. 2010 Jan;6(1):17-20. doi: 10.4161/hv.6.1.10332. Epub 2010 Jan 15.
Despite its small population and isolated location Papua New Guinea (PNG) with a malaria burden comparable to sub-Saharan Africa, its intense transmission of all four human Plasmodium species and an unrivalled combination of environmental and human variation offers unique perspectives on malaria vaccines. Building on a long history of malaria research, in this article we review past achievements, highlight current research and outline future directions in malaria vaccine research. With intensive transmission of all four species of human malaria, a full range of malaria endemicities, well described epidemiology and a demonstrated capacity to evaluate a malaria vaccine, PNG currently has the only field site that is ready to conduct proof-of-principle studies of currently available P. vivax vaccine candidates and future combined P. falciparum / P. vivax vaccines and also offers unique opportunities for P. falciparum vaccine research. PNG is thus ready to contribute significantly in the global malaria vaccine endeavor.
尽管巴布亚新几内亚（PNG）人口稀少且地处偏远，但其疟疾负担与撒哈拉以南非洲相当，四种人类疟原虫均在此高强度传播，加之无与伦比的环境和人类多样性组合，为疟疾疫苗研究提供了独特视角。基于长期的疟疾研究历史，在本文中，我们回顾过去的成就，突出当前的研究，并概述疟疾疫苗研究的未来方向。由于四种人类疟疾均在此高强度传播，涵盖了各种疟疾流行程度，流行病学描述详尽，且具备评估疟疾疫苗的能力，PNG目前是唯一准备好对现有间日疟原虫疫苗候选物以及未来的恶性疟原虫/间日疟原虫联合疫苗进行原理验证研究的现场，同时也为恶性疟原虫疫苗研究提供了独特机遇。因此，PNG准备好在全球疟疾疫苗事业中做出重大贡献。
